RU98123097A - CARBOXAMIDES BENZOFURANE AND THEIR THERAPEUTIC APPLICATION - Google Patents
CARBOXAMIDES BENZOFURANE AND THEIR THERAPEUTIC APPLICATIONInfo
- Publication number
- RU98123097A RU98123097A RU98123097/04A RU98123097A RU98123097A RU 98123097 A RU98123097 A RU 98123097A RU 98123097/04 A RU98123097/04 A RU 98123097/04A RU 98123097 A RU98123097 A RU 98123097A RU 98123097 A RU98123097 A RU 98123097A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- methoxy
- benzofurancarboxamide
- acetyl
- disease
- Prior art date
Links
- 230000001225 therapeutic Effects 0.000 title claims 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 35
- -1 heterocyclo Chemical group 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000006673 Asthma Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000001575 pathological Effects 0.000 claims 4
- QHKJIJXBJCOABP-UHFFFAOYSA-N 1-benzofuran-2-carboxamide Chemical compound C1=CC=C2OC(C(=O)N)=CC2=C1 QHKJIJXBJCOABP-UHFFFAOYSA-N 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 206010003246 Arthritis Diseases 0.000 claims 2
- 206010006451 Bronchitis Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000007451 Chronic Bronchitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 210000003979 Eosinophils Anatomy 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 201000002674 obstructive nephropathy Diseases 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 230000002685 pulmonary Effects 0.000 claims 2
- 201000006704 ulcerative colitis Diseases 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 206010001513 AIDS related complex Diseases 0.000 claims 1
- 208000010310 AIDS-Related Complex Diseases 0.000 claims 1
- 101700084127 AVP Proteins 0.000 claims 1
- 102100017238 AVP Human genes 0.000 claims 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims 1
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 1
- 108009000283 Allograft Rejection Proteins 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 208000001183 Brain Injury Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007515 Cardiac arrest Diseases 0.000 claims 1
- 206010052638 Cerebral injury Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000001187 Dyskinesias Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000003401 Eosinophilic Granuloma Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010018634 Gouty arthritis Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 210000001503 Joints Anatomy 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 208000009856 Lung Disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040070 Septic shock Diseases 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 230000000202 analgesic Effects 0.000 claims 1
- 230000000954 anitussive Effects 0.000 claims 1
- 230000002917 arthritic Effects 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 230000003182 bronchodilatating Effects 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 125000004470 heterocyclooxy group Chemical group 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000001272 neurogenic Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 201000004810 vascular dementia Diseases 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
Claims (35)
гдe Z представляет СО или CS;
R1 представляет алкоксигруппу, необязательно замещенную одним или несколькими галогенами, ОН или тиоалкилом;
R2 и R3 одинаковые или различные, и каждый представляет Н, R6, OR10, COR6, С(= NОR6)R6, алкил-С(= NОR6)R6 алкил-С(=NОН)R6, С(=NОН)R6, галоген, NR8R9, СF3, CN, CO2H, СО2R10, СОNН2, CONHR6 или CON(R6)2;
R4 представляет Н, арилалкил, гетероарилалкил, гетероциклоалкил, S(O)mR10 или алкил, необязательно замещенный одним или несколькими заместителями, выбранными из гидрокси, алкокси, CO2R7, SO2NR11R12, CONR11R12, СN, карбонильного кислорода, NR8R9, COR10 и S(O)nR10;
R5 представляет арил, гетероарил, гетероцикло, арилалкил, гетероарилалкил или гетероциклоалкил;
в R4 или R5 часть арил/гетероарил/гетероцикло необязательно замещена одним или несколькими заместителями алкил-R13 или R13;
R6 представляет R10 необязательно замещенный в любом положении R14;
R7 представляет Н, алкил, арилалкил, гетероарилалкил или гетероциклоалкил;
R8 представляют Н, арил, гетероарил, гетероцикло, алкил, циклоалкил, арилалкил, гетероарилалкил, гетероциклоалкил, алкилкарбонил, алкоксикарбонил, арилсульфонил, гетероарилсульфонил, гетероциклосульфонил, арилкарбонил, гетероарилкарбонил, гетероциклокарбонил или алкилсульфонил;
R10 представляет алкил, циклоалкил, арил, гетероарил, гетероцикло, арилалкил, гетероарилалкил или гетероциклоалкил;
R9, R11 или R12 одинаковые или различные, и каждый представляет Н или R10;
R13 представляет алкил, необязательно замещенный галогеном, алкокси, необязательно замещенный галогеном, арил, гетероарил, гетероцикло, гидрокси, арилокси, гетероарилокси, гетероциклоокси, арилалкилокси, гетероарилалкилокси, гетероциклоалкилокси, CO2R7, CONR11R12, SO2HR11R12, галоген, -CN, -NR8R9, COR10, S(O)nR10 или карбонильный кислород;
R14 представляет ОН, карбонильный кислород, OR10, NR8R9, СN, CO2H, CO2R10, CONR11R12 или COR10;
m равно целому числу до 2; и
n = 0-2;
или его фармацевтически приемлемая соль.1. The compound of the General formula
where Z is CO or CS;
R 1 represents an alkoxy group, optionally substituted with one or more halogen, OH or thioalkyl;
R 2 and R 3 are the same or different, and each represents H, R 6 , OR 10 , COR 6 , C (= NOR 6 ) R 6 , alkyl-C (= NOR 6 ) R 6 alkyl-C (= NOH) R 6 , C (= NON) R 6 , halogen, NR 8 R 9 , CF 3 , CN, CO 2 H, CO 2 R 10 , CONH 2 , CONHR 6 or CON (R 6 ) 2 ;
R 4 is H, arylalkyl, heteroarylalkyl, heterocycloalkyl, S (O) m R 10 or alkyl, optionally substituted with one or more substituents selected from hydroxy, alkoxy, CO 2 R 7 , SO 2 NR 11 R 12 , CONR 11 R 12 , CN, carbonyl oxygen, NR 8 R 9 , COR 10 and S (O) n R 10 ;
R 5 is aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;
in R 4 or R 5, the aryl / heteroaryl / heterocyclo portion is optionally substituted with one or more alkyl substituents R 13 or R 13 ;
R 6 is R 10 optionally substituted in any position; R 14 ;
R 7 is H, alkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;
R 8 is H, aryl, heteroaryl, heterocyclo, alkyl, cycloalkyl, arylalkyl, etho-heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxycarbonyl, arylsulfonyl, heteroarylsulfonyl, heterocyclosulfonyl, arylcarbonyl, hetero-alkylsulfonyl, heteroarylsulfonyl, heterocyclosulfonyl, arylcarbonyl, hetero-alkylsulfonyl, heteroarylsulfonyl, heterocycloalkyl, heteroxy-alkyl
R 10 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, or heterocycloalkyl;
R 9 , R 11 or R 12 is the same or different, and each is H or R 10 ;
R 13 represents alkyl optionally substituted with halogen, alkoxy optionally substituted by halogen, aryl, heteroaryl, heterocyclo, hydroxy, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, geterotsikloalkiloksi, CO 2 R 7, CONR 11 R 12, SO 2 HR 11 R 12 , halogen, -CN, -NR 8 R 9 , COR 10 , S (O) n R 10 or carbonyl oxygen;
R 14 is OH, carbonyl oxygen, OR 10 , NR 8 R 9 , CN, CO 2 H, CO 2 R 10 , CONR 11 R 12 or COR 10 ;
m is an integer up to 2; and
n = 0-2;
or its pharmaceutically acceptable salt.
2-этил-7-метокси-4-N-(3,5-дихлорпирид-4-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-[N-(пирид-4-ил)-N-пропил]бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-хлорфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2,6-диметилфенил)бенэофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(4-метоксифенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(3-бром-5-метилпирид-2-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(3-метилфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(3,5-дихлсрпирид-2-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-метилфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(4-метокси-2-метилфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(пиримидин-4-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-трифторметилфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-[2-(пиперидин-1-ил)фенил]бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(3-хлорпирид-4-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-трифторметоксифенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-этилфенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-бифенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(3-метилпирид-2-ил)бензофуранкарбоксамид,
2-этил-7-метокси-4-N-(2-хлорпирид-3-ил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-метоксифенил)бензофуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-хлорпирид-3-ил)бензсфуранкарбоксамид,
2-ацетил-7-метокси-4-N-(2-хлор-6-метилфенил)бенэофуранкарбоксамид,
2-(1-гидроксиэтил)-7-метокси-4-N-(3,5-дихлорпирид-4-ил)бензофуранкарбоксамид,
2-(3-пирид-3-ил-1-оксопропил)-7-метокси-4-М-(3,5-дихлорпирид-4-ил)бензофуранкарбоксамид,
2-(1-бензилоксиимино)этил-7-метокси-4-N-(3,5-дихлорпирид-4-ил)бензофуранкарбоксамид,
2-этил-7-метокси-4-N-(3-карбоксифенил)бензофуранкарбоксамид,
2-этил-7-метокси-4-N-(4-карбоксифенил)бензофуранкарбоксамид и
2-[1-(2,2-диметилпропил)]-7-метокси-4-N-(3,4-дихлорпирид-4-ил)бензофуранкарбоксамид.18. The compound according to claim 1, selected from the group including:
2-ethyl-7-methoxy-4-N- (3,5-dichloropyrid-4-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4- [N- (pyrid-4-yl) -N-propyl] benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-chlorophenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2,6-dimethylphenyl) benofurancarboxamide,
2-acetyl-7-methoxy-4-N- (4-methoxyphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (3-bromo-5-methylpyrid-2-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (3-methylphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (3,5-dichlspyrid-2-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-methylphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (4-methoxy-2-methylphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (pyrimidin-4-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-trifluoromethylphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- [2- (piperidin-1-yl) phenyl] benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (3-chloropyrid-4-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-trifluoromethoxyphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-ethylphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-biphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (3-methylpyrid-2-yl) benzofurancarboxamide,
2-ethyl-7-methoxy-4-N- (2-chloropyrid-3-yl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-methoxyphenyl) benzofurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-chloropyrid-3-yl) benzfurancarboxamide,
2-acetyl-7-methoxy-4-N- (2-chloro-6-methylphenyl) benofurancarboxamide,
2- (1-hydroxyethyl) -7-methoxy-4-N- (3,5-dichloropyrid-4-yl) benzofurancarboxamide,
2- (3-pyrid-3-yl-1-oxopropyl) -7-methoxy-4-M- (3,5-dichloropyrid-4-yl) benzofurancarboxamide,
2- (1-benzyloxyimino) ethyl-7-methoxy-4-N- (3,5-dichloropyrid-4-yl) benzofurancarboxamide,
2-ethyl-7-methoxy-4-N- (3-carboxyphenyl) benzofurancarboxamide,
2-ethyl-7-methoxy-4-N- (4-carboxyphenyl) benzofurancarboxamide and
2- [1- (2,2-dimethylpropyl)] - 7-methoxy-4-N- (3,4-dichloropyrid-4-yl) benzofurancarboxamide.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9610515.0A GB9610515D0 (en) | 1996-05-20 | 1996-05-20 | Novel compounds |
GB9610515.0 | 1996-05-20 | ||
WOPCT/GB96/03012 | 1996-12-05 | ||
WO???/GB96/03012 | 1996-12-05 | ||
PCT/GB1996/003012 WO1997020833A1 (en) | 1995-12-05 | 1996-12-05 | Benzofuran carboxamides and sulphonamides |
GB9708070.9 | 1997-04-22 | ||
GBGB9708070.9A GB9708070D0 (en) | 1997-04-22 | 1997-04-22 | Compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU98123097A true RU98123097A (en) | 2000-11-20 |
RU2162467C2 RU2162467C2 (en) | 2001-01-27 |
Family
ID=26309366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU98123097/04A RU2162467C2 (en) | 1996-05-20 | 1997-05-20 | Benzofuran carboxamides and pharmaceutical composition containing thereof |
Country Status (19)
Country | Link |
---|---|
US (2) | US5972936A (en) |
EP (1) | EP0901482B1 (en) |
JP (1) | JP2000510848A (en) |
CN (1) | CN1219171A (en) |
AT (1) | ATE239004T1 (en) |
BR (1) | BR9709113A (en) |
CA (1) | CA2252537A1 (en) |
CZ (1) | CZ371998A3 (en) |
DE (1) | DE69721526T2 (en) |
ES (1) | ES2193376T3 (en) |
HU (1) | HUP0100042A3 (en) |
IL (1) | IL126558A (en) |
NO (1) | NO985375D0 (en) |
NZ (1) | NZ332340A (en) |
PL (1) | PL329912A1 (en) |
RU (1) | RU2162467C2 (en) |
SK (1) | SK282676B6 (en) |
TR (1) | TR199802386T2 (en) |
WO (1) | WO1997044337A1 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020833A1 (en) * | 1995-12-05 | 1997-06-12 | Darwin Discovery Limited | Benzofuran carboxamides and sulphonamides |
AU4454597A (en) * | 1996-08-19 | 1998-03-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel benzofuran-4-carboxamides |
AU9281198A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzofuran derivatives |
WO1999040085A1 (en) * | 1998-02-09 | 1999-08-12 | Darwin Discovery Limited | Benzofuran-4-carboxamides and their therapeutic use |
AU4037799A (en) * | 1998-05-08 | 1999-11-29 | Smithkline Beecham Plc | Phenylurea and phenylthio urea derivatives |
TW555759B (en) * | 1998-06-08 | 2003-10-01 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
GB0003257D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
AU2001277731A1 (en) | 2000-08-09 | 2002-02-18 | Welfide Corporation | Fused bicyclic amide compounds and medicinal use thereof |
US6953774B2 (en) | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
KR20040075004A (en) | 2001-12-14 | 2004-08-26 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | Method of inducing ovulation using non-polypeptide camp level modulator |
WO2003090357A1 (en) * | 2002-04-19 | 2003-10-30 | Integrated Magnetoelectronics Corporation | Interfaces between semiconductor circuitry and transpinnor-based circuitry |
ES2195785B1 (en) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
DE10238257B4 (en) * | 2002-08-21 | 2007-04-19 | Johannes-Gutenberg-Universität Mainz | Sorbicillactone A and sorbicillactone A derivatives, process for their preparation and medicines containing them |
US20050215626A1 (en) * | 2003-09-25 | 2005-09-29 | Wyeth | Substituted benzofuran oximes |
ES2251866B1 (en) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
ES2251867B1 (en) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
JPWO2006088246A1 (en) * | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | GPR34 receptor function regulator |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2008014450A (en) | 2006-05-18 | 2009-03-09 | Mannkind Corp | Intracellular kinase inhibitors. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CN100434426C (en) * | 2006-10-10 | 2008-11-19 | 中国科学院昆明植物研究所 | Chinese sumac lactone A , preparation method and its use in pharmacy |
PL2114951T3 (en) | 2007-02-28 | 2014-10-31 | Leo Pharma As | Novel phosphodiesterase inhibitors |
ZA200905371B (en) * | 2007-02-28 | 2010-10-27 | Leo Pharma As | Novel phosphodiesterase Inhibitors |
ES2320954B1 (en) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | NEW PREPARATION PROCEDURE FOR 3-METHYL-4-PHENYLISOXAZOLO (3,4-D) IRIDAZIN-7 (6H) -ONA. |
KR100752613B1 (en) * | 2007-05-02 | 2007-08-29 | 우석대학교 산학협력단 | Foods for preventing arrhythmia comprising novel benzofuran derivatives |
CL2008001933A1 (en) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others. |
CN102216276A (en) | 2008-09-11 | 2011-10-12 | 辉瑞大药厂 | Heteroaryls amide derivatives and their use as glucokinase activators |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
DK2406253T3 (en) * | 2009-03-11 | 2013-08-12 | Pfizer | BENZOFURANIA DERIVATIVES USED AS GLUCOKINASE INHIBITORS |
UA109140C2 (en) * | 2010-06-24 | 2015-07-27 | Heterocyclic Benzodioxol Or Benzodioxepine Compounds As Phosphodiesterase Inhibitors | |
CN102010405B (en) * | 2010-11-08 | 2012-07-25 | 湖南大学 | 4-(benzofuran-5-yl)-2-benzal aminothiazole and application of 4-(benzofuran-5-base)-2-benzal aminothiazole as antineoplastic agent |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
US10196372B2 (en) | 2015-01-05 | 2019-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | MYC G-quadruplex stabilizing small molecules and their use |
AR119059A1 (en) * | 2019-06-04 | 2021-11-17 | Nippon Soda Co | COMPOUND OF BENZAMIDE AND HERBICIDE |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62155269A (en) * | 1984-12-29 | 1987-07-10 | Kaken Pharmaceut Co Ltd | Benzofuran derivative, production thereof and remedy for diabetic complication containing said derivative as active ingredient |
WO1992003427A1 (en) * | 1990-08-17 | 1992-03-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Ketone compound and remedy for osteoporosis |
CA2144763A1 (en) * | 1992-10-14 | 1994-04-28 | George D. Hartman | Fibrinogen receptor antagonists |
GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
ATE180780T1 (en) * | 1993-08-05 | 1999-06-15 | Hoechst Marion Roussel Inc | 2-(PIPERIDINE-4-YL, PYRIDINE-4-YL AND TETRAHYDROPYRIDINE-4-YL)-BENZOFURAN-7-CARBAMAT DERIVATIVES, THEIR PREPARATION AND USE AS ACETYLCHOLINESTERASE INHIBITORS |
DK0685475T3 (en) * | 1994-05-31 | 1999-08-30 | Bayer Ag | Amino-benzofuryl and thienyl derivatives |
RU2138498C1 (en) * | 1994-07-22 | 1999-09-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Dihydrobenzofurans, method of their synthesis and pharmaceutical composition on said |
AU5772296A (en) * | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
DK0771794T3 (en) * | 1995-05-19 | 2006-09-11 | Kyowa Hakko Kogyo Kk | Oxygen-containing heterocyclic compounds |
AU5772396A (en) * | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
WO1996036611A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
JPH10147585A (en) * | 1996-11-19 | 1998-06-02 | Kyowa Hakko Kogyo Co Ltd | Oxygen-containing heterocyclic compound |
WO1997020833A1 (en) * | 1995-12-05 | 1997-06-12 | Darwin Discovery Limited | Benzofuran carboxamides and sulphonamides |
AU4454597A (en) * | 1996-08-19 | 1998-03-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel benzofuran-4-carboxamides |
-
1997
- 1997-05-20 RU RU98123097/04A patent/RU2162467C2/en not_active IP Right Cessation
- 1997-05-20 US US08/859,510 patent/US5972936A/en not_active Expired - Fee Related
- 1997-05-20 EP EP97923193A patent/EP0901482B1/en not_active Expired - Lifetime
- 1997-05-20 SK SK1604-98A patent/SK282676B6/en unknown
- 1997-05-20 BR BR9709113A patent/BR9709113A/en active Search and Examination
- 1997-05-20 NZ NZ332340A patent/NZ332340A/en unknown
- 1997-05-20 US US08/859,509 patent/US5925636A/en not_active Expired - Fee Related
- 1997-05-20 TR TR1998/02386T patent/TR199802386T2/en unknown
- 1997-05-20 JP JP09541240A patent/JP2000510848A/en not_active Ceased
- 1997-05-20 AT AT97923193T patent/ATE239004T1/en not_active IP Right Cessation
- 1997-05-20 CA CA002252537A patent/CA2252537A1/en not_active Abandoned
- 1997-05-20 ES ES97923193T patent/ES2193376T3/en not_active Expired - Lifetime
- 1997-05-20 PL PL97329912A patent/PL329912A1/en unknown
- 1997-05-20 WO PCT/GB1997/001361 patent/WO1997044337A1/en not_active Application Discontinuation
- 1997-05-20 CN CN97194736A patent/CN1219171A/en active Pending
- 1997-05-20 DE DE69721526T patent/DE69721526T2/en not_active Expired - Fee Related
- 1997-05-20 IL IL12655897A patent/IL126558A/en not_active IP Right Cessation
- 1997-05-20 HU HU0100042A patent/HUP0100042A3/en unknown
- 1997-05-20 CZ CZ983719A patent/CZ371998A3/en unknown
-
1998
- 1998-11-19 NO NO985375A patent/NO985375D0/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU98123097A (en) | CARBOXAMIDES BENZOFURANE AND THEIR THERAPEUTIC APPLICATION | |
RU98123074A (en) | Quinoline Carboxamides as Inhibitors of TNF and PDE-IV | |
DE602004010848T2 (en) | DERIVATIVES OF 1-PIPERAZINE AND 1-HOMOPIPERAZINE CARBOXYLATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS INHIBITORS OF THE FAAH ENZYME | |
US5925636A (en) | Benzofuran carboxamides and their therapeutic use | |
DE69628019T2 (en) | CHINOLONES AND THEIR THERAPEUTIC USE | |
CA2436659A1 (en) | Cannabinoid receptor ligands | |
AR040803A1 (en) | CANABINOID RECEIVERS, PHARMACEUTICAL COMPOSITIONS, A PROCESS FOR THEIR DEVELOPMENT AND THE USE OF SUCH COMPOUNDS, ONLY OR COMBINED, FOR THE PREPARATION OF MEDICINES | |
RU99112569A (en) | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC APPLICATION | |
ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
JPH10511114A (en) | Novel N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands | |
RU96103653A (en) | Bicyclic Tetrahydropyrazolopyridines | |
CN1134146A (en) | Benzoyl guanidines, their production and their use in medicaments | |
CN1083830C (en) | Substituted benzamidines, their production and their use as medicaments | |
CH616673A5 (en) | ||
JP2008512374A5 (en) | ||
JP2010501587A5 (en) | ||
KR20090127307A (en) | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor | |
US5773467A (en) | Benzofuran sulphonanmides | |
DE112010005848B4 (en) | amide compounds | |
WO1998020007A1 (en) | Quinolines and their therapeutic use | |
JPH0867670A (en) | Use of substituted 4-phenyl-6-aminonicotinic acid derivativeas drug | |
JP2004520423A5 (en) | ||
JPS58225065A (en) | 2-quinolone derivative | |
CH636862A5 (en) | 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES SUBSTITUTED IN 2-POSITION, THEIR SALTS AND PROCESS FOR THEIR PRODUCTION. | |
DE3923675A1 (en) | AMONOALKYL-SUBSTITUTED 2-AMINOTHIAZOLES AND THERAPEUTICAL AGENTS CONTAINING THEM |